TCGA-18-4083-01A-01R-A96U-41
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.340
- MITOTIC_SPINDLE+0.290
- SPERMATOGENESIS+0.180
- DNA_REPAIR+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
- HEDGEHOG_SIGNALING+0.090
- WNT_BETA_CATENIN_SIGNALING-0.060
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- COAGULATION-0.430
- ESTROGEN_RESPONSE_EARLY-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.410
- COMPLEMENT-0.390
- ESTROGEN_RESPONSE_LATE-0.390
- ANGIOGENESIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-18-4083-01A-01R-1100-07 | — | cohortSQ2 | 0.948 |
| 2 | BS_3F5PR9GS | medulloblastoma | — | 0.937 |
| 3 | SRR1313143 | — | E | 0.936 |
| 4 | C3L-04013 | — | cohortMD1 | 0.926 |
| 5 | TCGA-52-7809-01A-21R-2125-07 | — | cohortMD1 | 0.926 |
| 6 | SRR8518301 | — | E | 0.923 |
| 7 | BS_FBJ5Q54N | Embryonal tumors | — | 0.922 |
| 8 | C3N-02283 | — | cohortMD1 | 0.920 |
| 9 | BS_7XQRH69M | medulloblastoma | — | 0.920 |
| 10 | SRR5088911 | — | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |